Obstet Gynecol Sci.  2018 Mar;61(2):242-246. 10.5468/ogs.2018.61.2.242.

The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins

• Shim YJ
• Seol A
• Lee D
• Kim SK
• Lee JR
• Jee BC
• Suh CS
• Kim SH

• KMID: 2420178
• DOI: http://doi.org/10.5468/ogs.2018.61.2.242

Abstract

OBJECTIVE
To investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation.
METHODS
This retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patients had previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes were compared according to the age of women (age < 35 vs. age ≥35) and the starting phase of ovarian stimulation (early follicular phase vs. late follicular phase vs. luteal phase).
RESULTS
Patients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintained at a low level (386.3±346.9 pg/mL). EOR was 52.4±78.8 pg/mL, and EMOR was 71.0±41.2 pg/mL. When the 2 groups were compared according to the age of women (age < 35 vs. age ≥35), EOR was 34.5 (22.2-46.5) pg/mL and 40.7 (19.3-65.3) pg/mL, respectively; EMOR was 79.8 (40.8-90.6) pg/mL and 68.8 (44.5-85.9) pg/mL, respectively. There was no significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase of ovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups.
CONCLUSION
Measuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a co-treatment of letrozole allows for the prediction of the numbers of oocytes and mature oocytes.

Keyword

Breast neoplasms; Fertility preservation; Aromatase inhibitors; Estradiol; In vitro fertilization

MeSH Terms

Aromatase Inhibitors
Breast Neoplasms*
Breast*
Estradiol
Female
Fertility Preservation
Fertilization in Vitro
Follicular Phase
Gonadotropins*
Humans
Oocytes
Ovulation Induction*
Retrospective Studies
Aromatase Inhibitors
Estradiol
Gonadotropins

Reference

1. Orvieto R, Hod E, Volodarsky M, Homburg R, Rabinson J, Meltcer S. Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones? Fertil Steril. 2008; 89:1269–1272.

2. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006; 91:3885–3890.

3. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008; 26:2630–2635.

4. Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci. 2015; 30:290–295.

5. Loumaye E, Engrand P, Howles CM, O'Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril. 1997; 67:889–899.

6. Vaughan DA, Harrity C, Sills ES, Mocanu EV. Serum estradiol:oocyte ratio as a predictor of reproductive outcome: an analysis of data from >9000 IVF cycles in the Republic of Ireland. J Assist Reprod Genet. 2016; 33:481–488.